On October 9, MetLife rose 3.09% in regular trading, trading at $98.74 per share, with turnover of $153 million. The move came as several investment banks raised their price targets, reinforcing positive sentiment toward the insurer.

Barclays lifted its target on MetLife to $111 from $97, maintaining an Overweight rating, while Piper Sandler upgraded the stock to Overweight from Neutral and raised its target to $110 from $99. The company also kept its quarterly dividend at $0.5925 per share, underscoring financial stability. Preliminary third-quarter variable investment income is estimated at a pre-tax level of at least $600 million, ahead of full results expected in November.

The average analyst rating for MetLife stands at Overweight with a mean price target of $108.93, according to FactSet, reflecting broad-based confidence following a series of upward revisions in recent months.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)